Free Trial

Trading of Scholar Rock was halted at 06:55 AM EST due to "News pending".

Scholar Rock (SRRK) Competitors

Scholar Rock logo
$33.75 +1.17 (+3.59%)
Closing price 04:00 PM Eastern
Extended Trading
$33.75 0.00 (0.00%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SRRK vs. ASND, VTRS, QGEN, BBIO, ROIV, ELAN, VRNA, MRNA, RVMD, and GRFS

Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Moderna (MRNA), Revolution Medicines (RVMD), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

Scholar Rock vs. Its Competitors

Scholar Rock (NASDAQ:SRRK) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Scholar Rock has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -127.11% -90.09%
Ascendis Pharma A/S -54.94%N/A -24.31%

Scholar Rock has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$33.19M97.75-$246.29M-$2.91-11.60
Ascendis Pharma A/S$393.54M30.37-$409.12M-$5.16-37.59

91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scholar Rock has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Scholar Rock currently has a consensus target price of $45.60, indicating a potential upside of 35.11%. Ascendis Pharma A/S has a consensus target price of $244.36, indicating a potential upside of 25.97%. Given Scholar Rock's stronger consensus rating and higher possible upside, research analysts plainly believe Scholar Rock is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.23
Ascendis Pharma A/S
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Scholar Rock had 34 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 40 mentions for Scholar Rock and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.84 beat Scholar Rock's score of 0.54 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
7 Very Positive mention(s)
5 Positive mention(s)
8 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Positive
Ascendis Pharma A/S
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Scholar Rock beats Ascendis Pharma A/S on 10 of the 17 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRRK vs. The Competition

MetricScholar RockMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.13B$3.17B$5.77B$10.52B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-11.6021.0476.4326.62
Price / Sales97.75409.14535.41119.74
Price / CashN/A46.3537.4661.85
Price / Book8.579.7813.616.45
Net Income-$246.29M-$52.73M$3.29B$271.57M
7 Day Performance4.36%2.40%1.67%2.83%
1 Month Performance-4.90%4.69%4.05%7.27%
1 Year Performance289.27%16.28%80.70%26.07%

Scholar Rock Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRRK
Scholar Rock
4.3393 of 5 stars
$33.75
+3.6%
$45.60
+35.1%
+247.0%$3.13B$33.19M-11.60140Trending News
Analyst Forecast
Gap Down
Trading Halted
High Trading Volume
ASND
Ascendis Pharma A/S
2.9738 of 5 stars
$194.62
-0.5%
$244.36
+25.6%
+29.9%$11.97B$393.54M-37.721,017
VTRS
Viatris
1.2878 of 5 stars
$9.60
-3.6%
$10.40
+8.3%
-14.0%$11.61B$14.74B-3.3132,000High Trading Volume
QGEN
QIAGEN
4.3617 of 5 stars
$45.39
+0.2%
$49.69
+9.5%
+4.7%$10.07B$1.98B26.825,765
BBIO
BridgeBio Pharma
4.4974 of 5 stars
$51.47
+0.5%
$63.94
+24.2%
+92.7%$9.79B$221.90M-12.58400
ROIV
Roivant Sciences
3.4223 of 5 stars
$13.95
-0.9%
$17.67
+26.6%
+24.8%$9.61B$29.05M-19.93860Trending News
Insider Trade
Analyst Revision
ELAN
Elanco Animal Health
2.5844 of 5 stars
$18.63
+0.5%
$17.33
-6.9%
+35.6%$9.21B$4.44B21.669,000
VRNA
Verona Pharma PLC American Depositary Share
2.0358 of 5 stars
$106.37
-0.1%
$109.00
+2.5%
+254.3%$9.17B$42.28M-107.4430Positive News
MRNA
Moderna
4.4611 of 5 stars
$23.88
+1.6%
$41.81
+75.1%
-59.6%$9.15B$3.24B-3.175,800Trending News
RVMD
Revolution Medicines
4.2884 of 5 stars
$46.20
-0.8%
$73.67
+59.5%
-2.2%$8.70B$11.58M-10.27250
GRFS
Grifols
3.9109 of 5 stars
$9.63
-2.5%
$10.30
+7.0%
+8.4%$6.79B$7.81B8.2323,822

Related Companies and Tools


This page (NASDAQ:SRRK) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners